President Trump recently announced plans for a 100% tariff on foreign brand-name drugs starting October 1, 2025. This news has left many people unsure about how it will affect their medications.
Trump’s post states that pharmaceutical companies will avoid the tariff if they build manufacturing plants in the U.S. However, it’s unclear exactly which drugs will be included. For instance, companies like Novo Nordisk and Eli Lilly are investing in U.S. facilities but whether that will exempt their products from tariffs remains ambiguous.
What Does This Mean for Patients?
Currently, only about 10% of prescriptions filled in the U.S. are for brand-name drugs; the rest are generics, which are generally cheaper. Experts suggest that price increases will depend on how many companies qualify for exemption from the tariff and whether they choose to pass costs onto consumers at the pharmacy counter.
Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School, warns, “Tariffs are taxes on patients.” If drugmakers face higher costs due to tariffs, they might raise prices. Yet, not all companies will likely pass these costs along immediately. For context, past tariffs have not resulted in significant increases for consumers.
The Bigger Picture: Insurers and Manufacturing
Insurance companies and pharmacy benefit managers might negotiate to absorb some of these costs. However, they are more likely to pass costs to patients, potentially through higher copays. Patients using government programs – Medicare, Medicaid, or Veterans Affairs – could face the most significant impacts.
As for spurring U.S. drug manufacturing, experts like Kesselheim are skeptical. Building a new plant takes years and faces regulatory hurdles. The Pharmaceutical Research and Manufacturers of America has warned that tariffs could divert funds away from investment in manufacturing and new treatments.
Concerns Over Shortages
If Trump focuses primarily on brand-name drugs, major shortages seem unlikely. Kesselheim notes that big companies have substantial profits and could manage the additional costs. However, smaller companies, particularly those that produce niche medications, might struggle to absorb these costs.
In an interesting twist, historical context shows that previous tariffs on healthcare products often led to discussions about shortages, especially regarding generics. Unlike branded drugs, generics are sold close to their manufacturing costs, leaving little room for companies to adapt to increased expenses.
Overall, the looming tariffs raise several questions about patient impact and the drug manufacturing landscape. As this situation unfolds, it will be crucial to monitor how companies respond and how it affects healthcare costs across the board.
For more insights on pharmaceutical policies, you can visit Health Affairs.
